If You Invested in Grifois, S.A. (GRFS)

Grifols, S.A. (NASDAQ: GRFS; MCE: GRF, GRF.P) is a global healthcare company in the pharmaceutical preparation manufacturing sector, with a long history dating back to its founding in Barcelona in 1909. The company focuses on essential plasma-derived medicines, transfusion medicine and related biopharmaceutical products and services that aim to improve the health and well-being of people around the world.

Grifols develops, produces and provides healthcare services and solutions in more than 110 countries. Its therapies and technologies are used to address many chronic, rare and prevalent conditions, often life-threatening, across therapeutic areas such as immunology, hepatology and intensive care, pulmonology, hematology, neurology, infectious diseases and critical care. According to company disclosures, patient needs and its growing knowledge of these conditions drive its innovation in both plasma and other biopharmaceuticals.

Plasma-derived medicines and biopharma focus

Grifols is described as a leader in plasma-derived medicines. It develops and manufactures protein-based therapies obtained from human plasma, which are used to treat conditions including primary and secondary immunodeficiencies and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), as noted in earlier descriptions of its business. The company’s immunoglobulin (IG) franchise is a core growth driver, with intravenous and subcutaneous formulations used as standard of care in primary and secondary immunodeficiencies and CIDP, according to its 2025 financial reports.

The company also reports activity in albumin, Alpha‑1 and specialty proteins. In its 2025 filings, Grifols highlights Alpha‑1 and specialty proteins as contributing to its biopharma performance and notes that it maintains a strong position in Alpha‑1 therapies. The biopharma segment is repeatedly cited as the main contributor to revenue growth in recent periods.

Global plasma collection network and infrastructure

Grifols describes itself as a pioneer in the plasma industry and states that it operates the world’s largest network of plasma donation centers. Company materials reference a network of close to 400–390+ centers across North America, Europe, Africa and the Middle East, and China. This network underpins its access to plasma for fractionation and supports its portfolio of plasma-derived medicines.

Over several decades of international expansion, Grifols has invested in a global network of donation, processing and distribution centers for plasma-derived medicines. In its 2025 half-year report, the company notes that this locally operated and vertically integrated model allows it to operate in regions including the United States, Europe, Egypt and Canada, and is intended to minimize reliance on cross-border imports or exports within the U.S. market.

Transfusion medicine, diagnostics and biological supplies

Beyond therapeutics, Grifols is a recognized participant in transfusion medicine. It offers a portfolio of solutions designed to enhance safety from donation to transfusion, together with clinical diagnostic technologies. Company disclosures describe revenues from its Diagnostic business unit, including blood typing solutions and molecular donor screening in the U.S., Europe and other key regions.

Grifols also supplies high-quality biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. In addition, it provides tools, information and services that support hospitals, pharmacies and healthcare professionals in delivering medical care. These activities complement its core plasma and biopharma operations.

Therapeutic areas and innovation examples

Across its communications, Grifols highlights a broad therapeutic focus. It is active in immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases, and more generally in critical care. Examples from recent news include:

• Immunoglobulins: XEMBIFY, a 20% subcutaneous immunoglobulin (SCIg) for primary humoral immunodeficiency, for which the U.S. Food and Drug Administration (FDA) approved an expanded label to include treatment‑naïve patients and biweekly dosing.
• Intravenous immunoglobulin: Yimmugo, an intravenous immunoglobulin developed by Biotest, a Grifols Group company, approved by the FDA for primary immunodeficiencies and produced at Biotest’s “Next Level” facility in Germany.
• Hemostasis and biosurgery: A plasma‑protein based fibrin sealant (FS) for controlling surgical bleeding, which received FDA approval for pediatric patients in the U.S. and is already approved for children and adults in Europe. The product is commercialized under brands such as VISTASEAL and VERASEAL through a collaboration with Johnson & Johnson MedTech.
• Ophthalmology and biodefense: Investigational ocular surface immunoglobulin (OSIG) eye drops being evaluated with the U.S. Biomedical Advanced Research and Development Authority (BARDA) as a potential treatment for sulfur mustard–induced ocular injury, and also being developed for dry eye disease.
• Neuroscience and biomarkers: The Chronos‑PD initiative, supported by a grant from The Michael J. Fox Foundation for Parkinson’s Research, to identify plasma-based biomarkers that may indicate increased likelihood of developing Parkinson’s disease years before clinical diagnosis.

Data assets, AI and research capabilities

Grifols reports that it has built a proprietary plasma sample bank of more than 100 million biospecimens collected over nearly 15 years, connected to real-world health data across thousands of disease states. This repository supports programs such as Chronos‑PD and is used by its subsidiary Alkahest, which specializes in AI and integrative analysis of multiomics and real-world data for diagnostic and therapeutic discovery.

The company describes using AI, proteomics and real-world evidence to search for disease-relevant signals in plasma, with the aim of developing new diagnostic tools and disease-modifying therapies. These activities illustrate how Grifols combines its plasma infrastructure with data and analytical capabilities.

Corporate structure, listings and scale

Grifols is headquartered in the Barcelona area of Spain and operates in more than 30 countries and regions. Company disclosures indicate that it employs more than 23,000–24,000 people worldwide and that its economic impact in core countries of operation has been significant, including direct, indirect and induced employment.

The company’s class A shares are listed on the Spanish Stock Exchange and are part of the IBEX‑35 index under the symbol GRF. Non‑voting class B shares are listed on the Mercado Continuo (GRF.P) and on the U.S. NASDAQ through American Depositary Receipts (ADRs) under the symbol GRFS.

Financial reporting and recent performance signals

As a foreign private issuer, Grifols files reports on Form 20‑F and Form 6‑K with the U.S. Securities and Exchange Commission. Recent 6‑K filings describe revenue growth driven mainly by the Biopharma segment, expansion of adjusted EBITDA margins, and efforts to strengthen free cash flow generation and reduce leverage. The company has reported improvements in its leverage ratio and liquidity, and in 2025 announced the reinstatement of a cash dividend, reflecting its capital allocation framework and focus on shareholder returns.

Grifols also references a Value Creation Plan aimed at enhancing free cash flow, optimizing capital allocation, and supporting deleveraging, while continuing to invest in its core plasma, immunoglobulin and diagnostic franchises.

Corporate governance and board developments

Grifols’ governance structure includes a Board of Directors and board committees. In a 2025 6‑K, the company reported amending its internal Board regulations to rename the Sustainability Committee as the “Sustainability, Communication and Reputation Committee” and to assign it responsibility for supervising corporate reputation. Another 6‑K in 2026 noted changes in the non‑member secretary and vice‑secretary roles of the Board of Directors.

External shareholders have publicly commented on governance matters. Letters from Mason Capital Management, a shareholder holding a minority stake in Grifols’ class A shares, have raised questions about related‑party transactions, board composition and disclosure practices. These letters, addressed to the Board and to the Spanish National Securities Market Commission (CNMV), reflect active engagement by some investors on corporate governance topics.

Strategic collaborations and subsidiaries

Grifols works with a range of partners and group companies. Examples mentioned in recent communications include:

• Biotest: A Grifols Group company that develops products such as Yimmugo and operates the Next Level production facility in Germany. Grifols has increased its equity stake in Biotest and completed the delisting of Biotest from the Frankfurt Stock Exchange.
• Johnson & Johnson MedTech: A collaboration for the marketing and distribution of Grifols’ fibrin sealant under brands such as VISTASEAL and VERASEAL, using Johnson & Johnson MedTech’s spray technology.
• BARDA: Partnerships to evaluate OSIG eye drops for sulfur mustard ocular injury and, through its GigaGen subsidiary, to develop recombinant polyclonal antibody therapies for certain biothreats.
• Selagine: A collaboration focused on developing immunoglobulin eye drops for dry eye disease.

Position within healthcare and manufacturing

Within the broader manufacturing sector, Grifols fits into pharmaceutical preparation manufacturing with a specialization in plasma-derived products, immunoglobulins and transfusion-related technologies. Its combination of a large plasma collection network, biopharma manufacturing, diagnostics, and data-driven research assets positions it as a diversified healthcare company centered on plasma science and related therapeutics.